• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Palvella Therapeutics, Inc. - Common Stock (NQ:PVLA)

    121.29 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EDT, May 8, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 1
    Open 121.29
    Bid (Size) 48.52 (200)
    Ask (Size) 123.00 (200)
    Prev. Close 121.29
    Today's Range 121.29 - 121.29
    52wk Range 20.20 - 151.18
    Shares Outstanding 98,935,025
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Palvella Therapeutics Q1 Earnings Call Highlights ↗
    Palvella Therapeutics (NASDAQ:PVLA) said it remains on track to submit a New Drug Application in the second half of 2026 for QTORIN rapamycin in Microcystic Lymphatic Malformations, after reporting... 
    Via MarketBeat
    Topics Earnings
    Palvella Therapeutics (NASDAQ:PVLA) Reports Wider Q1 Loss but NDA Submission Stay on Track ↗
    Via Chartmill

    Performance

    YTD
    +21.0%
    +21.0%
    1 Month
    -4.6%
    -4.6%
    3 Month
    +55.7%
    +55.7%
    6 Month
    +51.1%
    +51.1%
    1 Year
    +484.5%
    +484.5%

    More News

    Read More
    News headline image
    Palvella Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
    From Palvella Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Palvella Therapeutics Announces First Patients Dosed in Phase 2 LOTU Trial of Fast Track-Designated QTORIN™ Rapamycin for Clinically Significant Angiokeratomas
    From Palvella Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Palvella Therapeutics to Host First Quarter 2026 Financial Results and Corporate Update Conference Call on May 7, 2026
    From Palvella Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Palvella Therapeutics to Present QTORIN™ Rapamycin Results from Phase 3 SELVA and Phase 2 TOIVA Studies at the International Society for the Study of Vascular Anomalies World Congress 2026
    From Palvella Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Palvella Therapeutics Appoints John D. Doux, M.D., M.B.A., Dermatologist and Recognized Leader in Rare Skin Diseases, to Board of Directors
    From Palvella Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Palvella Therapeutics Appoints Accomplished Commercial Leader Kent Taylor as Senior Vice President of Sales
    From Palvella Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Palvella Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Update
    From Palvella Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Palvella Therapeutics Announces Scientific Publication in Journal of Vascular Anomalies Highlighting the Infiltrative Growth and Therapeutic Challenges of Microcystic Lymphatic Malformations
    From Palvella Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Palvella Therapeutics Highlights Continued Progress Across Rare Skin Disease Pipeline with Two Poster Presentations at the 2026 American Academy of Dermatology Annual Meeting
    From Palvella Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Palvella Stock Up 340% as Insider Sells Shares. Here's What the Move Does (And Does Not) Signal ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Director Buys $500,000 Worth of Palvella Therapeutics Shares After Phase 3 Win ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Palvella Therapeutics to Host Full Year 2025 Financial Results Conference Call and Provide a Corporate Update on March 31, 2026
    From Palvella Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Palvella Therapeutics Strengthens Leadership Team with Appointment of Rare Disease Commercial Leader Jennifer J. McDonough as Senior Vice President of Market Access and Patient Services
    From Palvella Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Palvella Therapeutics Announces Issuance of European Patent Covering Anhydrous Compositions of Rapamycin
    From Palvella Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Palvella Therapeutics Launches "BEYOND mLM" Disease Awareness Campaign for Microcystic Lymphatic Malformations in Collaboration with Leading Lymphatic, Vascular, and Dermatology Nonprofit Organizations
    From Palvella Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Palvella Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
    From Palvella Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Palvella Therapeutics Announces Pricing of Upsized Public Offering
    From Palvella Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Palvella Therapeutics Announces Proposed Public Offering
    From Palvella Therapeutics Inc.
    Via GlobeNewswire
    Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗
    Via Chartmill
    Tuesday's session: top gainers and losers ↗
    Via Chartmill
    Let's uncover which stocks are experiencing notable gaps during today's session. ↗
    Via Chartmill
    Which stocks are moving before the opening bell on Tuesday? ↗
    Via Chartmill
    News headline image
    Why Did PVLA Stock Surge 45% In Pre-Market Today? ↗
    Via Stocktwits

    Frequently Asked Questions

    Is Palvella Therapeutics, Inc. - Common Stock publicly traded?
    Yes, Palvella Therapeutics, Inc. - Common Stock is publicly traded.
    What exchange does Palvella Therapeutics, Inc. - Common Stock trade on?
    Palvella Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Palvella Therapeutics, Inc. - Common Stock?
    The ticker symbol for Palvella Therapeutics, Inc. - Common Stock is PVLA on the Nasdaq Stock Market
    What is the current price of Palvella Therapeutics, Inc. - Common Stock?
    The current price of Palvella Therapeutics, Inc. - Common Stock is 121.29
    When was Palvella Therapeutics, Inc. - Common Stock last traded?
    The last trade of Palvella Therapeutics, Inc. - Common Stock was at 05/08/26 04:00 PM ET
    What is the market capitalization of Palvella Therapeutics, Inc. - Common Stock?
    The market capitalization of Palvella Therapeutics, Inc. - Common Stock is 12.00B
    How many shares of Palvella Therapeutics, Inc. - Common Stock are outstanding?
    Palvella Therapeutics, Inc. - Common Stock has 12B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.